Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 17
2004 14
2005 16
2006 14
2007 9
2008 17
2009 11
2010 13
2011 14
2012 11
2013 20
2014 15
2015 12
2016 10
2017 17
2018 14
2019 24
2020 17
2021 16
2022 11
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Cortes JE, et al. Among authors: deininger m. Leukemia. 2024 Jul;38(7):1522-1533. doi: 10.1038/s41375-024-02278-8. Epub 2024 May 16. Leukemia. 2024. PMID: 38755421 Free PMC article. Clinical Trial.
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X, Kantarjian H. Jabbour E, et al. Among authors: deininger m. Leukemia. 2024 Mar;38(3):475-481. doi: 10.1038/s41375-024-02159-0. Epub 2024 Jan 29. Leukemia. 2024. PMID: 38287132 Free PMC article.
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ, Kim JJ, Pyne D, Travas A, Ambalavanan A, Kimura S, Deininger MW, Kim JW, Kim DDH. Han HJ, et al. Among authors: deininger mw. Leukemia. 2024 Feb;38(2):412-415. doi: 10.1038/s41375-023-02122-5. Epub 2023 Dec 28. Leukemia. 2024. PMID: 38155246 No abstract available.
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. Cross NCP, et al. Among authors: deininger m. Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4. Leukemia. 2023. PMID: 37794101 Free PMC article. Review.
Bioluminescence Assay of Lysine Deacylase Sirtuin Activity.
Van Scoyk AN, Antelope O, Franzini A, Ayer DE, Peterson RT, Pomicter AD, Owen SC, Deininger MW. Van Scoyk AN, et al. Among authors: deininger mw. bioRxiv [Preprint]. 2023 Aug 14:2023.08.10.552871. doi: 10.1101/2023.08.10.552871. bioRxiv. 2023. PMID: 37645727 Free PMC article. Preprint.
290 results